Astellas Pharma US, Inc.
NEWS
With the latest approval, Xtandi, an androgen receptor inhibitor, is now the only oral treatment approved by the FDA for three distinct types of advanced prostate cancer – non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mCSPC.
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
The experimental drug enfortumab vedotin, developed by Astellas and Seattle Genetics, demonstrated a 44% objective response rate in patients.
The federal anti-kickback statute prevents pharmaceutical companies from providing financial coverage of Medicare copay payments that would encourage patients to purchase a company’s medication.
During a presentation at the American Association for Cancer Research meeting over the weekend, Astellas touted new overall survival data for Xospata.
Seattle Genetics and Tokyo-based Astellas Pharma announced positive topline data from the first cohort of its Phase II EV-201 trial.
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
JOBS
IN THE PRESS